Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

Published 1 month, 3 weeks ago
Description
In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer therapy Anktiva, Merck agrees to acquire Terns Pharmaceuticals in a $6.7 billion deal while Shionogi moves to take full ownership of the Shionogi-Apnimed Sleep Science joint venture, and a new commentary examines the structural pricing problem sitting at the center of the GLP-1 access debate.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us